4.7 Letter

DuoStim reduces time to pregnancy, minimizes treatment discontinuation, and is potentially cost-effective

Related references

Note: Only part of the references are listed.
Review Obstetrics & Gynecology

Routine double-ovarian-stimulation (DuoStim) in poor responders lacks rationale, evidence, and follow-up

Angelo Tocci et al.

Summary: Double ovarian stimulation (DuoStim) is progressively used as a routine clinical IVF treatment, but there is a lack of rationale, evidence, and follow-up for this expansion. The authors suggest that DuoStim should only be used in controlled clinical trials with valid clinical indications and appropriate experimental consents.

HUMAN REPRODUCTION (2023)

Review Obstetrics & Gynecology

Fertility treatment and cancers-the eternal conundrum: a systematic review and meta-analysis

Jennifer Frances Barcroft et al.

Summary: Overall, fertility treatment does not significantly increase the risk of breast, ovarian, or endometrial cancer, and may even lower the incidence of cervical cancer. However, there may be an association between certain fertility treatments like IVF and clomiphene citrate and increased risk of ovarian cancer, warranting further investigation.

HUMAN REPRODUCTION (2021)

Review Genetics & Heredity

How effective are the non-conventional ovarian stimulation protocols in ART? A systematic review and meta-analysis

Demian Glujovsky et al.

JOURNAL OF ASSISTED REPRODUCTION AND GENETICS (2020)